EU/3/14/1341: Orphan designation for the treatment of cystinosis
Cysteamine hydrochloride
Table of contents
Overview
On 15 October 2014, orphan designation (EU/3/14/1341) was granted by the European Commission to Lucane Pharma SA, France, for cysteamine hydrochloride for the treatment of cystinosis.
Key facts
Active substance |
Cysteamine hydrochloride
|
Medicine name |
Dropcys
|
Intended use |
Treatment of cystinosis
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/14/1341
|
Date of designation |
15/10/2014
|
Sponsor |
Lucane Pharma SA
172 rue de Charonne 75011 Paris France Tel. +33 1 53 86 87 50 Fax +33 1 43 71 14 96 E-mail: info@lucanepharma.com |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: